(Q37668618)

21 August 2017

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities (English)

1 reference

21 August 2017

1 reference

ChEBI release 2020-05-28

Michelle Head

1

1 reference

PubMed ID

20050824

21 August 2017

Michael B Jameson

series ordinal

2

1 reference

PubMed ID

20050824

21 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

1 reference

21 August 2017

19

1 reference

21 August 2017

2

1 reference

21 August 2017

295-304

1 reference

Angiogenic attack as a therapeutic strategy for cancer

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Vascular-targeting therapies for treatment of malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Vascular disrupting agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Vascular disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Flavone acetic acid--preclinical and clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Antivascular therapy of cancer: DMXAA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

DMXAA: an antivascular agent with multiple host responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903540214

10.1517/13543780903540214

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

20050824